Insulin-Statin-PCSK9 Links Point to New Treatment Horizons

An intricate dance with the PCSK9 molecule played out by statins, diabetes, and risk markers may explain the prowess of evolocumab and alirocumab on LDL-C and points to a hypothetical use for the agents.
Heartwire from Medscape